A new study revealed that tocilizumab tocilizumab The anti-inflammatory, which is used for patients with rheumatoid arthritis, improves survival in patients with serious complications of the Corona virus, and American researchers in several hospitals in America, including Birmingham Hospital, investigated the effects of a drug tocilizumab Anti-inflammatory on patients with coronavirus.
According to the Medical website, unlike steroids, which suppress the immune system on a larger scale, tocilizumab specifically inhibits the pro-inflammatory cytokine receptor. IL-6.
And they found that when a drug was given tocilizumab During the first two days of admission to the intensive care unit, there was a 30% relative reduction (and an absolute decrease of 10%) in the mortality rate compared to patients whose treatment did not include the early use of tocilizumab. The results are published in JAMA Internal Medicine.
“Tocilizumab has been used for several years to treat a condition known as cytokine release syndrome, which can be observed in cancer patients receiving certain types of immunotherapy,” said senior author of the study.
He added, “It is in a state of spread COVID-19 It has been observed that many of the illnesses and deaths that occur may be due to the body’s inflammatory response to the virus rather than the virus itself.
The monoclonal antibody is currently approved tocilizumab For rheumatoid arthritis and giant cell arteritis, an inflammatory condition that affects large blood vessels.
Since the start of the epidemic, many studies have been done on tocilizumab in Europe and China, but there have been no studies of this size or precision.
The multicenter study used accumulated data from more than 4,000 patients in critical condition with COVID-19 They were admitted to intensive care units at 68 locations throughout the United States as part of a treatment and outcome study in critically ill patients with COVID-19 .
–
– .
